Asset Management One Co. Ltd. raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 23.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 82,688 shares of the biotechnology company’s stock after buying an additional 15,805 shares during the period. Asset Management One Co. Ltd. owned about 0.19% of United Therapeutics worth $9,722,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. BlackRock Inc. raised its stake in shares of United Therapeutics by 3.3% during the second quarter. BlackRock Inc. now owns 4,897,334 shares of the biotechnology company’s stock valued at $635,330,000 after acquiring an additional 155,349 shares in the last quarter. FMR LLC raised its stake in shares of United Therapeutics by 2.8% during the second quarter. FMR LLC now owns 4,254,841 shares of the biotechnology company’s stock valued at $551,980,000 after acquiring an additional 116,062 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of United Therapeutics by 0.7% during the second quarter. Vanguard Group Inc. now owns 3,810,146 shares of the biotechnology company’s stock valued at $494,291,000 after acquiring an additional 25,047 shares in the last quarter. State Street Corp raised its stake in shares of United Therapeutics by 0.9% during the second quarter. State Street Corp now owns 2,014,506 shares of the biotechnology company’s stock valued at $261,345,000 after acquiring an additional 17,179 shares in the last quarter. Finally, Schroder Investment Management Group raised its stake in shares of United Therapeutics by 42.8% during the second quarter. Schroder Investment Management Group now owns 1,091,675 shares of the biotechnology company’s stock valued at $143,359,000 after acquiring an additional 327,360 shares in the last quarter.

A number of equities analysts recently commented on the stock. ValuEngine raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 30th. Oppenheimer reissued a “buy” rating on shares of United Therapeutics in a research note on Friday, September 8th. TheStreet downgraded shares of United Therapeutics from a “b-” rating to a “c” rating in a research note on Friday, September 29th. BidaskClub raised shares of United Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. Finally, Cowen reissued a “hold” rating and issued a $129.00 price objective on shares of United Therapeutics in a research note on Friday, October 27th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $136.10.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 1,274 shares of the company’s stock in a transaction on Thursday, September 21st. The shares were sold at an average price of $116.07, for a total value of $147,873.18. Following the sale, the chief executive officer now directly owns 2,343 shares of the company’s stock, valued at $271,952.01. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,265 shares of the company’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $119.70, for a total transaction of $151,420.50. Following the completion of the sale, the chief executive officer now directly owns 2,334 shares in the company, valued at $279,379.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,411 shares of company stock worth $2,601,966. 7.80% of the stock is owned by corporate insiders.

Shares of United Therapeutics Co. (NASDAQ:UTHR) opened at $137.41 on Friday. The firm has a market cap of $5,940.00, a price-to-earnings ratio of 11.97 and a beta of 1.42. United Therapeutics Co. has a 1-year low of $112.01 and a 1-year high of $169.89.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, beating analysts’ consensus estimates of $4.01 by $2.26. The firm had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the company earned $4.23 earnings per share. analysts anticipate that United Therapeutics Co. will post 12.45 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/17/united-therapeutics-co-uthr-holdings-lifted-by-asset-management-one-co-ltd.html.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related stocks with our FREE daily email newsletter.